CELC — Celcuity Inc.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1603454 ·
Last close
$134.26
Market Cap
$6.55B
52W High
$151.02
52W Low
$100.01
ADV30
1,077,700
Next earnings
2026-08-13
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -50,507,000 -52,841,000 410,164,000 145,191,000 356,639,000
Dec 2025 0 -49,201,000 -50,973,000 466,558,000 165,703,000 366,003,000
Sep 2025 0 -42,849,000 -43,804,000 476,004,000 74,252,000 359,041,000
Jun 2025 0 -44,009,000 -45,268,000 183,592,000 46,354,000 139,217,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-153,280,000
Investing CF
$-64,084,000
Financing CF
$360,552,000
CapEx
$-249,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.79
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-448,897,000
Inventory
Receivables
ST Investments
$275,794,000
EBIT TTM
$-159,894,000
Pretax Income TTM
$-177,042,000
Interest Exp TTM
$17,148,000
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -172,192,000 -177,042,000 466,558,000 366,003,000 -153,280,000
Dec 2024 0 -113,267,000 -111,779,000 245,123,000 129,504,000 -83,467,000
Dec 2023 0 -66,230,331 -63,779,116 191,219,398 51,450,076 -53,812,253
Dec 2022 0 -39,391,091 -40,370,040 175,697,097 41,925,630 -36,008,171

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.74

Peers — same industry

TickerNameMarket CapLastDaily %
PACS PACS Group, Inc. $6.15B $38.87
CHE CHEMED CORP $5.81B $437.33
HIMS Hims & Hers Health, Inc. $5.32B $23.85
UHS UNIVERSAL HEALTH SERVICES INC $8.35B $156.63
SHC Sotera Health Co $4.55B $15.96

News headlines (Yahoo Finance, 1h cache)

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer
2026-05-19 21:05 · Yahoo
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
2026-05-17 20:46 · Yahoo
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 20:07 · Yahoo
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision
2026-05-16 09:18 · Yahoo
Celcuity Inc (CELC) Q1 2026 Earnings Call Highlights: Promising Clinical Trials and Strategic ...
2026-05-15 05:02 · Yahoo
Celcuity Q1 Earnings Call Highlights
2026-05-14 23:10 · Yahoo
Celcuity (CELC) Q1 2026 Earnings Transcript
2026-05-14 21:52 · Yahoo
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:01 · Yahoo
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
2026-05-14 11:30 · Yahoo
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
2026-05-10 11:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.